U.S. Markets closed
  • S&P Futures

    4,464.33
    -9.92 (-0.22%)
     
  • Dow Futures

    34,696.80
    -52.20 (-0.15%)
     
  • Nasdaq Futures

    15,486.67
    -31.08 (-0.20%)
     
  • Russell 2000 Futures

    2,241.04
    +7.84 (+0.35%)
     
  • Crude Oil

    71.37
    -0.60 (-0.83%)
     
  • Gold

    1,749.20
    -2.20 (-0.13%)
     
  • Silver

    22.42
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1714
    -0.0018 (-0.1523%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3710
    -0.0027 (-0.1961%)
     
  • USD/JPY

    109.9000
    +0.0050 (+0.0046%)
     
  • BTC-USD

    45,700.88
    -2,163.40 (-4.52%)
     
  • CMC Crypto 200

    1,143.52
    -82.01 (-6.69%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

AstraZeneca ties up with IQVIA to speed up studies of COVID-19 vaccine candidate

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Reuters) - Life sciences company IQVIA Holdings Inc said on Tuesday it would collaborate with AstraZeneca Plc to speed up clinical studies of the British drugmaker's potential COVID-19 vaccine in the United States.

The collaboration is part of the U.S. government's Operation Warp Speed to accelerate the development of COVID-19 vaccines and treatments.

AstraZeneca is among the drugmakers farthest along in the race to develop a safe and effective vaccine for COVID-19, the respiratory disease caused by the new coronavirus. The British drugmaker has received U.S. funding of more than $1 billion to secure access to dosages.

The agreement includes an expansive study of trial participants and will use IQVIA's virtual trial solutions that would make parts of the study remote.

Clinical trial service providers like IQVIA have seen a boost in demand for their offerings in virtual care - an area that has been slow to catch on - as the pandemic forces people to self-isolate and stay at home.

(Reporting by Vishwadha Chander in Bengaluru)